ReviewCancers2023
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Predicting ki-67 expression in breast cancer via transformer and multiple instance learning on DCE-MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.BMC medical imaging · 2026Article
- Noninvasive prediction of Ki67 proliferation index in breast cancer based on integrated photoacoustic imaging.BMC medical imaging · 2026Article
- Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies.Cancers · 2026Review
- Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer.Frontiers in medicine · 2026Article
- A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population.Frontiers in medicine · 2026Article
- Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Predicting dynamic changes of Ki-67 in breast cancer after neoadjuvant therapy based on multi-phase DCE-MRI delta-radiomics.Frontiers in oncology · 2026Article
- Predictors and nomogram for upstaging to invasive breast carcinoma in ductal carcinomaGland surgery · 2025Article
- Omission of Sentinel Lymph Node Biopsy in Early-Stage HER2+ and Triple-Negative Breast Cancer: A Retrospective Analysis.Journal of personalized medicine · 2025Article
- Contrast-enhanced ultrasound as a non-invasive diagnostic modality for pancreatic ductal adenocarcinoma: The question of Ki67 for study validation.World journal of gastrointestinal oncology · 2025Article
- Predictive value of serum glutathione S-transferase (GST-â), P-glycoprotein (PGP), P53, KI-67 in breast cancer: A systematic review and meta-analysis.Journal of medical biochemistry · 2025Article
- Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients.Discover oncology · 2025Review
- Advanced Deep Learning Approaches in Detection Technologies for Comprehensive Breast Cancer Assessment Based on WSIs: A Systematic Literature Review.Diagnostics (Basel, Switzerland) · 2025Review
- The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.Breast cancer research and treatment · 2025Article
- Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.Health science reports · 2025Article
- The value of morphological magnetic resonance imaging features combined with diffusion kurtosis imaging for predicting Ki-67 expression levels in high-grade gliomas.Quantitative imaging in medicine and surgery · 2025Article
- Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.Cancer medicine · 2025Article
- Androgen Receptor and Tumor-Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics.International journal of breast cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 1983 discovery of a mouse monoclonal antibody-the Ki-67 antibody-that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation in breast cancer and other solid tumors. Cellular proliferation is a central determinant of prognosis and response to cytotoxic chemotherapy in patients with breast cancer, and since the discovery of the Ki-67 antibody, Ki-67 has evolved as an important biomarker with both prognostic and predictive potential in breast cancer. Although there is universal recognition among the international guideline recommendations of the value of Ki-67 in breast cancer, recommendations for the actual use of Ki-67 assays in the prognostic and predictive evaluation of breast cancer remain mixed, primarily due to the lack of assay standardization and inconsistent inter-observer and inter-laboratory reproducibility. The treatment of high-risk ER-positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer with the recently FDA-approved drug abemaciclib relies on a quantitative assessment of Ki-67 expression in the treatment decision algorithm. This further reinforces the urgent need for standardization of Ki-67 antibody selection and staining interpretation, which will hopefully lead to multidisciplinary consensus on the use of Ki-67 as a prognostic and predictive marker in breast cancer. The goals of this review are to highlight the historical evolution of Ki-67 in breast cancer, summarize the present literature on Ki-67 in breast cancer, and discuss the evolving literature on the use of Ki-67 as a companion diagnostic biomarker in breast cancer, with consideration for the necessary changes required across pathology practices to help increase the reliability and widespread adoption of Ki-67 as a prognostic and predictive marker for breast cancer in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.